anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The usual cardiology care group will receive usual care provided by the HF clinic. We will assess symptoms and QoL at enrollment and symptoms, QoL, satisfaction, advance care planning documentation, and resource utilization at follow up 6 months later.
A photochromic self-tanning composition is used for changing the skin color between darker and lighter tans according to the ultraviolet light. The photochromic self-tanning composition includes a carrier, a tanning agent, a self-tanning agent and a photochromic agent. The tanning agent is spread on the skin to appear suntan color. The self-tanning agent is used for coloring the skin to appear suntan color. The photochromic agent is used for absorbing the ultraviolet light, and then emitting the visible light. The visible light emitted by the photochromic agent pluses the suntan color so that the skin appears relatively darker tan.
Participants will complete the 2 questionnaires online, one week or more apart. Once questionnaires are completed they will be invited to attended the 75 minute physical literacy workshop. The workshop content and delivery will be the same as the intervention group but will not include questionnaires.
Blood transfusion has been associated with worse outcomes in pediatric cardiac surgical patients. The major complications associated with it include increased blood loss during and after surgery, kidney disease requiring dialysis, abnormal coagulation profile, increased vasopressor use, and increased time spent on the ventilator and in the intensive care unit. One strategy to minimize blood product administration is acute normovolemic hemodilution (ANH). The investigators primary aim is to determine if ANH for pediatric cardiac surgical patients decreases the volume of blood products transfused during surgery and the immediate post-operative period, compared to usual care. The investigators designed a randomized, controlled, open label study that equally assigns 24 pediatric cardiac surgery patients aged 6 months to 3 years into two groups to receive either ANH prior to initiating cardiopulmonary bypass or usual standard of care. Participants in the ANH arm of the study will have 10 ml/kg of blood removed following anesthetic induction. In order to maintain normal circulating volume, the collected blood will be replaced with an equal volume of 5% albumin. All participants will be treated with a standardized protocol aimed at blood conservation including the use of retrograde arterial and antegrade venous perfusion, small circuit size, intraoperative red blood cell salvage, and low hemoglobin targets to trigger transfusion.
There is a direct correlation between being overweight and iron deficiency. Physiological changes occur in obese adipose cells that contribute to the development of iron deficiency (ID) and iron deficiency anemia (IDA). These changes disrupt the normal iron metabolic checks and balances. Furthermore, bariatric surgery can lead to long-term ID and IDA. Oral iron supplementation may not be effective for many of these patients. Intravenous iron infusions can significantly increase the quality of life for individuals experiencing this condition but are also associated with potentially serious complications. Adequate knowledge about intravenous (IV) iron administration can greatly increase the safety of this beneficial therapy. This review article explains the relationship between obesity, ID/IDA, bariatric surgery and the safe administration of IV iron.
OBJECTIVE: Radiation necrosis is becoming an increasingly prevalent complication in patients with brain tumors given the growing utility of stereotactic radiosurgery in modern treatment paradigms. Magnetic resonance-guided laser interstitial thermal therapy (MRgLITT) is a new minimally invasive modality that has exhibited an efficacy comparable to craniotomy in treating radiation necrosis. No studies to date have compared their cost-effectiveness despite the significant additional expenses associated with MRgLITT use. This study aimed to evaluate the cost-effectiveness of MRgLITT versus craniotomy in patients with comparable presentations of radiation necrosis.
METHODS: The National Inpatient Sample (NIS) was queried from 2011 to 2020 for patients with radiation necrosis and treated using craniotomy or MRgLITT. Admission charges and costs were inflation adjusted to 2020 $US. Surgical cohorts were propensity score-matched according to demographic, clinical, and admission characteristics. Multivariable linear and logistic regression analyses identified associations between type of intervention and outcomes. A semi-Markov model was created to simulate treatment with craniotomy versus MRgLITT. Cost, transition probabilities, and health state utilities were derived from the NIS, individual patient outcomes from multiple institutions, and prospectively collected quality-of-life data from a single institution and verified against other studies. Monte Carlo simulation and probabilistic sensitivity analysis were used to evaluate the cost-effectiveness between the two modalities.
RESULTS: In the designated study period, 2869 patients had been admitted with brain tumor radiation necrosis and were managed with neurosurgical intervention. After propensity score matching, MRgLITT, relative to craniotomy, was independently associated with a shorter length of stay (LOS; β = -1.81, p = 0.002), lower odds of complications (OR 0.18, p = 0.033), and higher odds of home discharge (OR 3.05, p = 0.041), but there was no difference in total admission costs between the two modalities (β = $6229, p = 0.081). On Monte Carlo simulation, patients treated with MRgLITT had a lower probability of disease (radiation necrosis or tumor) recurrence (13.5% vs 22.0%, p < 0.001) but an equivalent mortality risk (22.8% vs 22.3%, p = 0.429) compared to the patients treated with craniotomy at the 1-year follow-up. Over a 4-year time horizon, MRgLITT had an incremental cost of -$25,685 and incremental effectiveness of 0.14 quality-adjusted life-year (QALY), resulting in an incremental cost-effectiveness ratio of -$183,464 per QALY relative to craniotomy.
CONCLUSIONS: MRgLITT was a more cost-effective treatment strategy than craniotomy in the management of patients with brain tumor radiation necrosis. The cost-effectiveness of MRgLITT may be attributed to a shorter LOS, lower complication odds, and higher home discharge odds in the immediate postoperative period and a lower risk of disease recurrence over the long-term follow-up.
Methylphenidate hydrochloride is a mild central nervous system (CNS) stimulant. Methylphenidate hydrochloride is available as 5, 10, and 20 mg tablets for oral administration.

Methylphenidate hydrochloride is methyl α-phenyl-2-piperidineacetate hydrochloride, and its structural formula is:

Methylphenidate hydrochloride is a white, odorless, fine crystalline powder. Its solutions are acid to litmus. It is freely soluble in water and in methanol, soluble in alcohol, and slightly soluble in chloroform and in acetone. Its chemical formula is C14H19NO2•HCl, and its molecular weight is 269.77.

Inactive Ingredients: Lactose, magnesium stearate, microcrystalline cellulose, sodium starch glycolate; 5 mg contains D&C Yellow #10; 10 mg contains FD&C Green #3, and 20 mg contains FD&C Yellow #6.
PROBLEM TO BE SOLVED: To provide a method for producing an intermediate for a naphthalene derivative having a steroid C17,20 inhibiting function, or the like, by a reduced number of steps in a high yield without using a heavy metal compound. SOLUTION: This method comprises reacting a compound represented by formula I (A is imidazole) or its salt with a compound represented by the formula R-M1 [R is a hydrocarbon or a heterocyclic ring; and M1 is an alkaline metal or the formula Mg-Y1 (Y1 is a halogen)] or its salt, e.g. isopropyl magnesium, and then reacts the product with an acid, e.g. sulfuric acid, to form a compound represented by formula II, e.g. 1-(1H-imidazol-4-yl)-2-methyl-propanene. These reactions are normally effected in a solvent (e.g. tetrachydrofuran) in the presence of water, preferably at -20 to 100 deg.C for approximately 5 minutes to 48 hours. It is preferable to add the acid to the product at 1 to 50 equivalents per equivalent of the compound represented by formula I. The compound represented by formula II is a useful intermediate for a compound represented by formula III.
PURPOSE: A method and system for managing a health using the Internet is provided to supply the optimum prescription for members at the optimum time by measuring numerical values of a blood cholesterol, a corpulence, and a glycosuria of a member in a health managing web site and supplying various prescriptions through the Internet. CONSTITUTION: A client(10) connects to the Internet(20) through a client program such as a PC or an Internet TV mounted in a house or an office. The Internet(20) is a network for transmitting and receiving data through a communication in a remote place. A plurality of hospitals(30) are cooperated with a health managing web site(50), investigates blood samples of clients, and transmits numerical values of blood cholesterol, corpulence, and a glycosuria to the web site(50). A plurality of research institutes(40) investigate blood samples of clients, and transmits gene information related to blood cholesterol, corpulence, and a glycosuria to the web site(50). The health managing web site(50) investigates numerical values of blood cholesterol, corpulence, and a glycosuria of members and the gene information thereof and supplies various prescriptions for members.
Two sessions of manualized MDMA-assisted psychotherapy with flexible dose of MDMA from 80 to 120 mg and optional supplemental dose 1.5 to 2 hours later. MDMA sessions are preceded by 3 non-drug preparatory psychotherapy sessions and followed by 3 integrative non-drug psychotherapy sessions.
Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogue inhibitors, including entecavir, alone or in combination with antiretrovirals. A majority of these cases have been in women. Obesity and prolonged nucleoside inhibitor exposure may be risk factors. Particular caution should be exercised when administering nucleoside analogue inhibitors to any patient with known risk factors for liver disease; however, cases have also been reported in patients with no known risk factors.  
  
Lactic acidosis with entecavir use has been reported, often in association with hepatic decompensation, other serious medical conditions, or drug exposures. Patients with decompensated liver disease may be at higher risk for lactic acidosis. Treatment with entecavir should be suspended in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity (which may include hepatomegaly and steatosis even in the absence of marked transaminase elevations).
The study will be conducted in the clinic of the Atatürk University Faculty of Dentistry, Department of Restorative Dental Treatment. After the participants fulfil the inclusion criteria, no interventional procedures other than the treatments routinely applied in the clinic will be performed. Participants who apply to the clinic with the need for dental caries treatment will be included in the study if they accept it. Before the treatment, anamnesis will be taken from the participants, and their information (age, gender) will be recorded. If necessary, local anaesthesia will be applied before or after opening the cavity. If anaesthesia is applied, they will be asked whether they feel numbness. In the study, a total of 180 teeth in 5 groups will be restored with 5 different composite resins.

Group 1: Omnichroma Group 2: Vittra Aps Unique Group 3: OneShade Group 4: Charisma Diamond Group 5: Clearfil Majesty Posterior

Then, the cavity will be prepared by using diamond rond and steel rond drills in class 2 cavity preparation. After the enamel surfaces of the teeth are roughened and washed with 37% orthophosphoric acid for 30 seconds, the necessary isolation will be provided with cotton pellets and saliva absorbent. Teeth will be fixed with matrix band and wedge systems. The adhesive bond system will be applied to all surfaces of the cavity with a bonding brush according to the manufacturer's instructions. Air will be gently applied to the cavity surface to create a shiny surface with an air gun. It will then be polymerised with an LED light device. Next, five different resin composites will be placed in the respective cavities and polymerised again with the light device. Finishing operations will be performed with a diamond-lobed milling cutter, and polishing operations will be performed with rubber systems. To evaluate the clinical success of the restorations, participants will be called at 1 week (baseline), 6 months, and 1 year to be evaluated by two specialists using FDI criteria and modified USPHS criteria, and the results will be recorded.
FIELD: organic chemistry. SUBSTANCE: synthesis is carried out by reaction of cooled to 0 C solution of 2,2-(2,5-dioxopiperazinyl-1,4)-diacetic acid diethyl ester in the medium of absolute methanol with dry NH(saturation for 40 min). Yield is 82.4%, m. p. is 313-315 C, empirical formula is CHNO, toxicity LDis above 1000 mg/kg. New substance shows protective effect against damage factors of histotoxic hypoxia, acute hypobaric hypoxia, improves conditioned reflex reproduction without effect on the processes of teaching and memorizing in mice. Synthesized compound can be used in medicine. EFFECT: synthesis of new compound indicated above. 4 tbl
Most patients with thyroid disease present with a thyroid nodule. Tools utilized to assess thyroid nodules and to rule out thyroid cancer include: serum thyroid function tests (TSH and thyroid hormone level), thyroid ultrasound (US), radionuclide scintigraphy (low activity I-131, I-123 and/or Tc99m), and fine needle aspiration (FNA) for cytology (cells) examination. High thyroid hormone levels (T4 or T3) and a low TSH level may indicate a nodule is a benign hyperfunctioning nodule (adenoma), thereby tending to rule out thyroid cancer. In such cases, thyroid imaging (US or scintigraphy) determines whether the nodule is hyperfunctioning whereas thyroid cancers appear under-functioning or “cold” on the scan. Graves’ disease and Hashimotos’ thyroiditis represent thyroid diseases which occur in children who have autoimmune thyroid disease. In these patients, abnormal thyroid function tests reflect underlying thyroid disease but do not exclude thyroid cancer.

The administration of radioiodine has proved to be an excellent method of destruction of over functioning thyroid tissue (either diffuse or toxic nodular goiter). Radioiodine is concentrated in the thyroid, destroying cells that concentrate it.

Surgical removal is the treatment of choice for thyroid carcinomas. At 2 to 4 months post surgery, a whole-body I-131 scan is performed following cessation of thyroxin drug for 4-6 weeks prior to the scan, thereby causing hypothyroidism; TSH then rises and stimulates iodide uptake. Iodine-containing foods and contrast media are avoided. Patients with significant I-131 uptake are given ablative (100 - 150 mCi) doses of I-131. For minimal uptake, doses of 30-50 mCi I-131 are given on an outpatient basis. Patients with extra thyroidal uptake from metastatic disease may be given larger doses of greater than 100 mCi.

I-131 THERAPY CAPSULE MARKET BACKGROUND

I-131 Therapy Capsule formulations provide an enhanced safety profile for nuclear medicine professionals. Oral solutions raise the risk for spills during administration in addition to the not uncommon scenario where very ill patients reject oral solution treatment; whereupon vomiting episodes create large areas of high level radiation spill. Oral solutions, however, are sold at deep discounts as compared to Therapy Capsules.

While many U.S. facilities have moved to adopt ALARA recommendations to reduce radiation exposure to healthcare workers which reasonably include routinely ordering encapsulated high activity I-131; the scenario also exists that the intended patient may not be able to swallow the Therapy Capsule for reasons including: the large size of competitive suppliers, as well as intubated, quadriplegia and/or severe swallowing difficulties. In these instances, it is particularly beneficial to have the ability to dissolve the capsule so that the patient may be treated on the same day, without having to order additional preparation.

Thank you,

AnazaoHealth Corporation
Degenerative cervical myelopathy (DCM) describes a spectrum of disorders that cause progressive and chronic cervical spinal cord compression. The clinical presentation can be complex and can include locomotor impairment, hand and upper extremity dysfunction, pain, loss of bladder and bowel function, as well as gastrointestinal dysfunction. Once diagnosed, surgical decompression is the recommended treatment for DCM patients with moderate to severe impairment. Our body is composed of a large community of microorganisms, known as the microbiota. Traumatic and non-traumatic spinal cord injuries (SCIs) can induce changes in the gut microbiota and gut microbiota derived metabolites. These changes have been reported as important disease-modifying factors after injury. However, whether gut dysbiosis is associated with functional neurological recovery after surgical decompression has not been examined to date. Here, DCM was induced in C57BL/6 mice by implanting an aromatic polyether material underneath the C5-6 laminae. The extent of gut dysbiosis was assessed by gas chromatography and 16S rRNA sequencing from fecal samples before and after decompression. Neuromotor activity was assessed using the Catwalk test. Our results show that DCM pre- and post- surgical decompression is associated with gut dysbiosis, without altering short chain fatty acids (SCFAs) levels. Significant differences in Clostridia, Verrumicrobiae, Lachnospiracea, Firmicutes, Bacteroidales, and Clostridiaceae were observed between the DCM group (before decompression) and after surgical decompression (2 and 5 weeks). The changes in gut microbiota composition correlated with locomotor features of the Catwalk. For example, a longer duration of ground contact and dysfunctional swing in the forelimbs, were positively correlated with gut dysbiosis. These results show for the first time an association between gut dysbiosis and locomotor deterioration after delayed surgical decompression. Thus, providing a better understanding of the extent of changes in microbiota composition in the setting of DCM pre- and post- surgical decompression.
Novel peptoids of alpha -substituted Trp derivatives useful as agents in the treatment of obesity, hypersecretion of gastric acid in the gut, gastrin-dependent tumors, or as antipsychotics are disclosed. Further the compounds are antianxiety agents and antiulcer agents. They are agents useful for preventing the response to withdrawal from chronic treatment or use of nicotine, diazepam, alcohol, cocaine, caffeine, or opioids. The compounds are also useful in the treatment and/or prevention of panic attacks. Also disclosed are pharmaceutical compositions and methods of treatment using the peptoids as well as processes for preparing them and novel intermediates useful in their preparation. An additional feature of the invention is the use of the subject compounds to prepare diagnostic compositions.
Lentils will be fortified with iron in the lab setting at the Crop Development Center (CDC) of The University of Saskatchewan, Canada. The study will fortify lentil by spraying iron fortificant NaFeEDTA solution. A small sprayer will be placed at the beginning of the lentil polishing machine at a commercial lentil mill located near Saskatoon, Canada. The iron solution will be applied as a fine mist which will be absorbed into the lentil as it travels through the polishing drum. As the fortified lentil leaves the drum it will be bagged in 20 kg food grade bags. The expected concentration of Fe in the final product will be approximately 21 mg/100 g of lentil (fortified with NaFeEDTA solution with 1600 ppm of Fe).
PURPOSE:To obtain a liver fenesta dilating and increasing agent of high safety which is used for treating chronic hepatopathy by using pantethine as an active ingredient. CONSTITUTION:The objective preparation is obtained by mixing pantethine, as an active ingredient, with an excipient such as starch or cellulose, a disintegrator, a stabilizer and other additives in a usual manner. It can be prepared into tablets, powder, granules, capsules or injection. The dose is 200-2,000mg/ day/adult in case of oral administration. The liver fenestae are small pores distributing in the endothelial cells and act as a filter between the liver cells and the blood to transport and exchange the substances. The long-term loading of cholesterol reduces the fenestrae, but the administration of pantethine dilates them and increase the number.
Patients will undergo radiological and clinical examination at the Duchess of Kent Children Hospital. Patients will be required to put on a pair of hand gloves with 18 IMUs located on specific bony landmarks (distal phalanges of fingers, proximal phalanges of index fingers and thumbs, dorsum of the hands and bilateral wrists).
Young adults, aged 20-35 years, experience the greatest rate of weight gain, averaging 1-2 lbs/yr. Over time, this weight gain is associated with a worsening in cardiovascular disease risk factors and an increase in the prevalence of metabolic syndrome. Given the difficulties in producing sustained weight loss later in life, preventing weight gain from occurring during this critical period is key to curbing the obesity epidemic. The Study of Novel Approaches for Prevention (SNAP) is a 2-center randomized trial designed to test whether behavioral interventions based on self-regulation can prevent weight gain in young adults (18-35 years; body mass index (BMI) 21-30 kg/m2). Approximately 600 participants will be recruited over two years and randomly assigned to a control condition (N=200), self-regulation with small changes (N=200) or self-regulation with large changes (N=200). The Small Changes group will be taught to make small, consistent, changes in eating and exercise behavior to prevent weight gain or reverse weight gain if it occurs whereas the Large Changes group will emphasize periodic, larger changes in eating and exercise, with a goal of producing weight loss and thereby providing a buffer against anticipated weight gain. The primary aim of the trial is to test whether the magnitude of weight gain from baseline across an average planned follow-up of three years differs across the three groups, with a priori hypotheses that weight gain will be greater in the Control group than in either intervention and greater in the Small Changes than Large Changes group. Secondary aims are to compare the three groups on a) the proportion of participants in the three groups who gain less than 1 pound over the planned follow-up, b) the mean difference in weight gain from baseline to 24-month follow-up, c) the changes in behaviors and psychosocial measures (diet, physical activity, dietary restraint, frequency of self-weighing,depression, and occurrence of abnormal eating behaviors), and d) the changes in cardiovascular disease risk factors (blood pressure, lipids, insulin sensitivity, and waist circumference). The trial will also examine the association among changes in behaviors, weight, and cardiovascular disease risk factors and examine variables that may moderate the effects of the intervention (including gender, ethnicity, initial BMI, age) and potential mediators of the effects of the intervention (including changes in diet, activity, and self-regulatory behaviors). SNAP is member of the Early Adult Reduction in Weight Through Lifestyle Interventions (EARLY) consortium of clinical trials funded by the National Heart, Lung, and Blood Institute.